Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood–Brain–Barrier Integrity

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Neurobiology

• Publication date

  2015-11-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12035-015-9533-3PMID 26572637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Injury-Induced Neurogenesis

  2016cited by this paper
• Effects of neural progenitor cells on post-stroke neurological impairment—a detailed and comprehensive analysis of behavioral tests

  2014cited by this paper
• Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model

  2014influential reference
• The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review.

  2014cited by this paper
• Paradigms of protein degradation by the proteasome.

  2014cited by this paper
• Neurogenesis and Inflammation after Ischemic Stroke: What is Known and Where We Go from Here

  2014cited by this paper
• Effects of acute versus post-acute systemic delivery of neural progenitor cells on neurological recovery and brain remodeling after focal cerebral ischemia in mice

  2014cited by this paper
• Exacerbation of ischemic brain injury in hypercholesterolemic mice is associated with pronounced changes in peripheral and cerebral immune responses.

  2014cited by this paper
• The unique functions of tissue-specific proteasomes.

  2014cited by this paper
• Targeting the ubiquitin proteasome system: beyond proteasome inhibition.

  2013cited by this paper
• From bortezomib to other inhibitors of the proteasome and beyond.

  2013cited by this paper
• Roles for HIF-1α in neural stem cell function and the regenerative response to stroke.

  2012cited by this paper
• The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis.

  2012cited by this paper
• Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation.

  2012cited by this paper
• The proteasome in health and disease.

  2012cited by this paper
• Intermittent Hypoxia after Transient Focal Ischemia Induces Hippocampal Neurogenesis and c-Fos Expression and Reverses Spatial Memory Deficits in Rats

  2011cited by this paper
• Novel proteasome inhibitors to overcome bortezomib resistance.

  2011cited by this paper
• Stroke and the immune system: from pathophysiology to new therapeutic strategies.

  2011cited by this paper
• Acute Hepatocyte Growth Factor Treatment Induces Long-Term Neuroprotection and Stroke Recovery via Mechanisms Involving Neural Precursor Cell Proliferation and Differentiation

  2011cited by this paper
• Mutant Ubiquitin-Mediated β-Secretase Stability via Activation of Caspase-3 is Related to β-Amyloid Accumulation in Ischemic Striatum in Rats

  2010cited by this paper
• Angiogenesis, neurogenesis and brain recovery of function following injury.

  2010cited by this paper
• BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma

  2010cited by this paper
• O2 regulates stem cells through Wnt/β-catenin signalling

  2010cited by this paper
• Temporal and spatial dynamics of cerebral immune cell accumulation in stroke.

  2009cited by this paper
• Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia.

  2009cited by this paper
• Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat

  2009cited by this paper
• Hypoxia inducible factor 1 as a therapeutic target in ischemic stroke.

  2009cited by this paper
• Anti-VEGF receptor antagonist (VGA1155) reduces infarction in rat permanent focal brain ischemia.

  2008cited by this paper
• Role of proteasomes in disease

  2007cited by this paper
• Protein Aggregation and Proteasome Dysfunction After Brain Ischemia

  2007cited by this paper
• Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib.

  2007cited by this paper
• Stroke-Induced Immunodepression: Experimental Evidence and Clinical Relevance

  2007cited by this paper
• The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia.

  2006cited by this paper
• Experimental Stroke Induces Massive, Rapid Activation of the Peripheral Immune System

  2006cited by this paper
• The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.

  2005cited by this paper
• Tripeptide Mimetics Inhibit the 20 S Proteasome by Covalent Bonding to the Active Threonines*

  2005cited by this paper
• Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator

  2005cited by this paper
• Emerging roles of proteasomes in ischemia-reperfusion injury of organs.

  2004cited by this paper
• Delayed Treatment with MLN519 Reduces Infarction and Associated Neurologic Deficit Caused by Focal Ischemic Brain Injury in Rats via Antiinflammatory Mechanisms Involving Nuclear Factor-κB Activation, Gliosis, and Leukocyte Infiltration

  2003cited by this paper
• Neuronal replacement from endogenous precursors in the adult brain after stroke

  2002cited by this paper
• The proteasome: a new target for novel drug therapies.

  2001cited by this paper
• Postischemic (6-Hour) Treatment With Recombinant Human Tissue Plasminogen Activator and Proteasome Inhibitor PS-519 Reduces Infarction in a Rat Model of Embolic Focal Cerebral Ischemia

  2001cited by this paper
• Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia.

  2000cited by this paper
• Neuroprotection achieved with a novel proteasome inhibitor which blocks NF‐κB activation

  2000cited by this paper

• Kaempferol promotes angiogenesis through HIF-1α/VEGF-A/Notch1 pathway in ischemic stroke rats.

  2025cites this paper
• Activation of the 20S proteasome core particle prevents cell death induced by oxygen- and glucose deprivation in cultured cortical neurons

  2024influential citation
• Successful AAV8 readministration: Suppression of capsid‐specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease

  2023cites this paper
• Bortezomib Is Toxic but Induces Neurogenesis and Inhibits TUBB3 Degradation in Rat Neural Stem Cells

  2023cites this paper
• Molecular chaperones in stroke-induced immunosuppression

  2023cites this paper
• Mild Traumatic Brain Injury Induces Time- and Sex-Dependent Cerebrovascular Dysfunction and Stroke Vulnerability

  2022cites this paper
• Effects of ischemic postconditioning and long non-coding RNAs in ischemic stroke

  2022cites this paper
• Long-term treatment with chloroquine increases lifespan in middle-aged male mice possibly via autophagy modulation, proteasome inhibition and glycogen metabolism

  2022cites this paper
• Inhibition of the immunoproteasome LMP2 ameliorates ischemia/hypoxia-induced blood–brain barrier injury through the Wnt/β-catenin signalling pathway

  2021cites this paper
• Pathophysiology of ischemic reperfusion injury and the molecular targets involved in amelioration of brain injury by herbal medicine

  2021cites this paper
• Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action

  2020cites this paper
• The Role of Ubiquitin-Proteasome Pathway and Autophagy-Lysosome Pathway in Cerebral Ischemia

  2020cites this paper
• Sequential activation of necroptosis and apoptosis cooperates to mediate vascular and neural pathology in stroke

  2020cites this paper
• Ginsenoside Rd attenuates blood-brain barrier damage by suppressing proteasome-mediated signaling after transient forebrain ischemia

  2020cites this paper
• A meta-analysis of remote ischaemic conditioning in experimental stroke

  2020cites this paper
• Lithium modulates miR‐1906 levels of mesenchymal stem cell‐derived extracellular vesicles contributing to poststroke neuroprotection by toll‐like receptor 4 regulation

  2020cites this paper
• Assessment of the neuroprotective efficacy of poly-arginine-18 (R18) peptides in a pre-clinical model of perinatal hypoxic-ischaemic encephalopathy (HIE)

  2018cites this paper
• Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat

  2018influential citation
• Total Flavonoids in Caragana (TFC) Promotes Angiogenesis and Enhances Cerebral Perfusion in a Rat Model of Ischemic Stroke

  2018influential citation
• Inhibition of immunoproteasome promotes angiogenesis via enhancing hypoxia-inducible factor-1α abundance in rats following focal cerebral ischaemia.

  2018cites this paper
• Perinatal Hypoxic-Ischemic Encephalopathy and Neuroprotective Peptide Therapies: A Case for Cationic Arginine-Rich Peptides (CARPs)

  2018cites this paper
• Protein Modifications with Ubiquitin as Response to Cerebral Ischemia-Reperfusion Injury

  2017cites this paper
• Assessment of the neuroprotective potential of poly-arginine peptides in stroke models

  2017cites this paper
• Neuroprotective efficacy of poly-arginine R18 and NA-1 (TAT-NR2B9c) peptides following transient middle cerebral artery occlusion in the rat.

  2017cites this paper
• Nrdp1 Increases Ischemia Induced Primary Rat Cerebral Cortical Neurons and Pheochromocytoma Cells Apoptosis Via Downregulation of HIF-1α Protein

  2017cites this paper
• Adaptive preconditioning in neurological diseases – therapeutic insights from proteostatic perturbations

  2016cites this paper
• The R18 Polyarginine Peptide Is More Effective Than the TAT-NR2B9c (NA-1) Peptide When Administered 60 Minutes after Permanent Middle Cerebral Artery Occlusion in the Rat

  2016cites this paper